The fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg pairs a GLP-1 receptor agonist with a long-acting analogue of amylin, a pancreatic hormone that reduces appetite and slows gastric emptying

Clinical Safety Screens Performed MTC personal AND family history in the comorbidity multi-select MEN-2 personal AND family history separately Substance / opioid screen with three-month opiate window + free-text dose, frequency, dates Suicidality and recent suicide attempt as exclusionary opt-out Active cancer treatment and cancer-free-for-five-years exclusionary End-stage kidney and liver disease opt-out Severe GI screen (gastroparesis, blockage, IBD) Pancreatitis history in the multi-select Self-reported blood pressure range and resting heart rate Past 2-month GLP-1 use (semaglutide / tirzepatide / none) No validated PHQ-2 or PHQ-9 depression instrument suicidality is captured as a binary exclusionary opt-out and severe depression is a checkbox on the comorbidity multi-select, but the validated brief screening scale is not used
Abizaid A, Liu ZW, Andrews ZB, et al
This medicine may cause serious allergic reactions, including anaphylaxis and angioedema
Repeated freeze-thaw cycles degrade peptide integrity by promoting aggregation and oxidation of susceptible residues